VENUS®
Enjoy Innovations

VRL/SEC/NSE 04.05.2012

National Stock Exchange of India Ltd..
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Outcome of Board Meeting held on May 04, 2012

Dear Sir/Madam,

This is to inform you that the Board of Directors at its meeting held today , have approved Unaudited Financial Results (Provisional) for the quarter ended 31/03/2012 .

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Kodan
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL

UKAS UKAS

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 04 May 2012 17:22 P 1

VENUS
Enjoy Innovations

VRL/SEC/NSE 04.05.12

National Stock Exchange of India Ltd..
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Unaudited Financial Results (Provisional) for the quarter ended 31.03.2012

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results (Provisional) for the quarter ended 31.03.12 alongwith Limited Review Report, which were taken on record by the Board of Directors at its meeting held on 04.05.12.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Kodan
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 04 May 2012 17:22 P 2

VENUS®
Enjoy Innovations

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 31st MARCH, 2012

(Rs. in Millions)

S. No.	Particulars	Quarter Ended on			Year Ended on	
	Part - I	31/03/2012 Unaudited	31/12/2011 Unaudited	31/03/2011 Unaudited	31/03/2012 Unaudited	31/03/2011 Audited
1	Net Sales/ Income from operations	1146.28	954.22	964.62	4049.22	3,572.73
2	Other Income	2.65	5.08	0.98	10.97	3.22
	Total Income	1,148.93	959.30	965.60	4,060.19	3,575.95
3	Total Expenditure :					
	(a) (Increase)/ Decrease in stock in trade	0.21	(2.94)	(48.48)	(90.33)	(39.03)
	(b) Consumption of raw materials	646.48	528.58	570.02	2321.22	2,037.88
	(c) Staff Cost	60.86	61.87	56.63	243.98	208.80
	(d) Other expenditure	198.98	168.12	140.07	678.72	549.31
	Total	906.53	755.63	718.24	3,153.59	2,756.96
	EBDIT	242.40	203.67	247.36	906.60	818.99
4	Interest	69.73	66.81	52.88	256.11	187.07
5	Depreciation	21.91	26.45	25.26	101.14	84.35
6	Profit/ (Loss) before tax (1+2-3-4-5)	150.76	110.41	169.22	549.35	547.57
7	Provision for Taxation	(4.84)	07.09	33.73	36.69	72.79
8	Net Profit/ (Loss) (6-7)	155.60	103.32	135.49	512.66	474.78
9	Paid up Equity Share Capital	97.42	91.42	91.29	97.42	91.29
10	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	2,332.69
11	E.P.S - Basic not annualised for the qtr	15.97	11.30	14.84	52.62	52.01
	- Annualised	63.89	45.21	59.37	52.62	52.01
	Part-II (A) PARTICULARS OF SHAREHOLDING					
1	Public Shareholding					
	- Number of Shares	6388986	6388986	6376092	6388986	6376092
	- Percentage of Shareholding	65.58	69.89	69.84	65.58	69.84
2	Promoters and promoter group shareholding					
	a) Pledged as collateral security to bank					
	- Number of Shares	1930000	1930000	1930000	1930000	1930000
	- Percentage of shares(as a% of the total shares	57.56	70.10	70.10	57.56	70.10
	- Percentage of shares (as a % of the total shares capital	19.81	21.11	21.14	19.81	21.14
	b) Non – Encumbered					
	- Number of Shares	1423002	823002	823002	1423002	823002
	- Percentage of shares (as a% of the total shares holding of promoter and promoter group)	42.44	29.89	29.89	42.44	29.89
	- Percentage of shares (as a % of the total shares capital	14.61	9.00	9.01	14.61	9.01

	Particulars	3 months ended 31.03.12
(B)	INVESTOR COMPLAINTS	
	- Pending at the beginning of the quarter	NIL
	- Received during the quarter	1
	- Disposed of during the quarter	1
	- Remaining unresolved at the end of the quarter	NIL

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL

UKAS QUALITY MANAGEMENT

UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 04 May 2012 17:22 P 3

VENUS®
Enjoy Innovations

Notes:

1. The above Un-audited (Provisional) financial Results for the period ended 31.03.12 were reviewed by the Audit Committee and taken on record at the board Meeting on 04.05.2012

2. During the Quarter:

a) Company has received 'BioSpectrum product of the year 2012' award for its once a day painkiller product Achnil.

b) The Company has entered Japan Market with patent approval for its novel research product Vancoplus.

3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.

4. During the Quarter, one investor grievances was received which was resolved and no investor grievance was pending at the end of the quarter.

5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

(Pawan Chaudhary)
Chairman & Managing Director

Place : Panchkula
Date : 04.05.2012

FROM :VENUS FAX NO. :0172 2565566 04 May 2012 17:23 P 4

J. K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022
0172-270 4536-37 Fax : 0172-270 4537
E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited,
51-52, Industrial Area, Phase – I,
Panchkula.

We have reviewed the accompanying statement of Unaudited Financial Results of **Venus Remedies Limited** for the Period ended 31.03.2012, prepared pursuant to clause 41 of the Listing Agreement. This Financial Statement is the responsibility of the company's Management.

We have conducted our review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists principally of applying analytical procedures for financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. We have not performed an audit and, accordingly, we do not express an audit opinion

Based on our review as aforesaid nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **J.K. Jain & Associates**
Chartered Accountants

J. K. Jain
(CA J.K. Jain)
Partner
M.No.083140

Date : 01.05.2012
Place : Chandigarh

CERTIFIED TO BE TRUE COPY

For Venus Remedies Limited

(Company Secretary)

FROM :VENUS FAX NO. :0172 2565566 04 May 2012 17:23 P 5